Intravitreal Ranibizumab (Lucentis) For Macular Oedema In Central Retinal Vein Occlusion (CRVO) In A Malaysian Population Setting

1. Kenneth C S Fong
2. Linda S L Ong
3. Iqbal Tajunisah
4. Mohd Hassan

University of Malaya Eye Research Centre (UMERC), Department of Ophthalmology, University of Malaya, Kuala Lumpur, Malaysia

Purpose:
To determine the efficacy and safety of intravitreal ranibizumab in the treatment of CRVO

Methods:
Prospective interventional case series. 9 eyes of 9 consecutive patients diagnosed with macular edema secondary to CRVO within 1 to 6 months of onset were recruited. Best corrected visual acuity (BCVA) using LogMAR letters and optical coherence tomography (OCT) measurements were performed at baseline and at 6 months. Intravitreal ranibizumab 0.5mg was given monthly for 3 months and then patients were followed up monthly for 1 year. Patients were retreated if there was recurrence of macular oedema on OCT central subfoveal thickness (CST) measurement.

Results:
The mean BCVA improved from 17.2 letters at baseline to 26 letters at 6 months follow-up (p=0.01). The mean CST decreased from 486 m at baseline to 313 m at 6 months follow-up (p=0.023). A mean number of 4.3 injections were required over the 6 month period. No complications occurred.

Conclusion:
Intravitreal ranibizumab provided rapid and sustained improvement in BCVA and CST in CRVO-related macular oedema in a Malaysian population.